Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling Eli Lilly supplier therapeutic strategy for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon secretion. GLP-1 derivatives demonstrate promising therapeu